Rallying to the Challenge 2024: recorded to watch again

Day 1 Playlist

Presentations

What do we mean by “Cell Vulnerabilities and Therapeutics?” What will be discussed during Grand Challenges in Parkinson’s Disease and why is it important
Simon Stott, Ph.D. — Cure Parkinson’s

What do cells do in response to protein aggregation? 
Thomas Goralski, M.S. — Henderson Lab, Van Andel Institute

What can go wrong with cells in Parkinson’s 1: Genetics
Vanessa Howland, Ph.D. — Van Andel Institute 

Genetics as a treatment target: an overview of what’s going on
Aleksandra Pilcicka — Cure Parkinson’s

Mitochondrial DNA damage — a biomarker for PD?
Professor Laurie Sanders — Duke University

Mitochondria as a treatment target: An overview of what’s going on
Aleksandra Pilcicka — Cure Parkinson’s

How can we see if a treatment might work in humans? iPSC cell modelling?
Professor Edward Fon — MCgill University

How the MiND Program is contributing to our knowledge about Parkinson’s — Types of biological sampling
Erin Williams, Ph.D. — MiND Program, Van Andel Institute

Day 2 Playlist

Presentations

What is gene therapy?
Dr. Matthias Luz — AskBio

Ask Bio: AAV2 GDNF
Professor Alan Whone — University of Bristol

What is Cell Replacement Therapy for Parkinson’s?
Roger Barker, MBBS, MRCP, Ph.D. — University of Cambridge

What cell replacement and gene therapy studies are underway? What stage are they at and how do the approaches compare?
Aleksandra Pilcicka — Cure Parkinson’s